ggwpq- Thanks for your comments as they are very much appreciated. Please, take a look at Rybellsus (Oral Semaglutide for T2D that is a peptide) vs. Ozempic (SubQ Semaglutide for T2D that is a peptide) for comparison.
The starting Rybelsus dosage is 3 mg by mouth, once daily for 30 days. After that, the dosage is increased to 7 mg once daily. Based on response, the dosage may be increased to a maximum of 14 mg daily. You should take Rybelsus in the morning at least 30 minutes before ingesting anything else.
Typical Ozempic dosing schedule:
Month 1: 0.25 mg injected once weekly for 4 weeks.
Month 2: 0.5 mg injected once weekly for 4 weeks.
Month 3: 1 mg injected once weekly for 4 weeks (optional)
Month 4 and beyond: 2 mg injected once weekly (optional)
So a great deal more Semaglutide is delivered orally for Rybelsus than SubQ for Ozempic but I believe Ozempic is generally thought to support better efficacy but has the advantage of being oral.
Also again notice that at least compared to Rybelsus, If they get 20 mg at some point (and it is an if) Viking is once again attempting some aggressive titration with their plan over only 28 days. IMO if tolerability is good, blood plasma concentration is proven under these circumstances, it should be a huge win for VKTX VK2735. One other note I will make is that the sequential design really lengthened the study. I assume they did that and were careful on the dosing as they had some high uncertainty as to what will be found and wanted to be every flexible on dosing to not cause any safety issues. On weight loss, they may well need a much longer study to prove weight loss and make the oral form of VK2735 a go to drug for maintenance.
News 
Market Data 
Discover 
